Skip to Content

IL-17 Targeted Drugs Signal Hope for Hidradenitis Suppurativa Patients

Dermatologist Thrasyvoulos Tzellos discussed exciting advancements in the treatment of Hidradenitis Suppurativa at the EADV congress. New drugs targeting IL-17, such as secukinumab, Bimekizumab and upatacitinib, show very promise in managing inflammation and draining fistulas, surpassing previous anti-TNF treatments.

Thrasyvoulos Tzellos

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top